Derma Sciences (NASDAQ: DSCI) is one of 82 public companies in the “Advanced Medical Equipment & Technology” industry, but how does it contrast to its rivals? We will compare Derma Sciences to similar businesses based on the strength of its earnings, analyst recommendations, valuation, risk, dividends, profitability and institutional ownership.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Derma Sciences and its rivals, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Derma Sciences 0 1 0 0 2.00
Derma Sciences Competitors 416 2180 3385 122 2.53

As a group, “Advanced Medical Equipment & Technology” companies have a potential downside of 21.00%. Given Derma Sciences’ rivals stronger consensus rating and higher probable upside, analysts plainly believe Derma Sciences has less favorable growth aspects than its rivals.

Risk & Volatility

Derma Sciences has a beta of 1.03, suggesting that its stock price is 3% more volatile than the S&P 500. Comparatively, Derma Sciences’ rivals have a beta of 0.89, suggesting that their average stock price is 11% less volatile than the S&P 500.

Profitability

This table compares Derma Sciences and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Derma Sciences -20.97% -17.10% -12.43%
Derma Sciences Competitors -330.24% -33.51% -12.50%

Valuation and Earnings

This table compares Derma Sciences and its rivals revenue, earnings per share (EPS) and valuation.

Gross Revenue EBITDA Price/Earnings Ratio
Derma Sciences N/A N/A -17.50
Derma Sciences Competitors $2.02 billion $430.37 million -58.32

Derma Sciences’ rivals have higher revenue and earnings than Derma Sciences. Derma Sciences is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Institutional & Insider Ownership

58.9% of Derma Sciences shares are held by institutional investors. Comparatively, 53.1% of shares of all “Advanced Medical Equipment & Technology” companies are held by institutional investors. 9.9% of Derma Sciences shares are held by company insiders. Comparatively, 16.8% of shares of all “Advanced Medical Equipment & Technology” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Derma Sciences rivals beat Derma Sciences on 6 of the 11 factors compared.

About Derma Sciences

Derma Sciences, Inc. (Derma Sciences) is a medical device company. The Company operates through two segments: advanced wound care and traditional wound care products. Advanced wound care products principally consist of both novel and otherwise differentiated dressings, devices and skin substitutes designed to promote wound healing and/or prevent infection. The Company’s advanced wound care product line consists of MEDIHONEY, TCC-EZ, AMNIOEXCEL and AMNIOMATRIX, XTRASORB and BIOGUARD. Traditional wound care products principally consist of commodity related dressings, ointments, gauze bandages, adhesive bandages, wound closure strips, catheter fasteners and skin care products. The Company’s traditional wound care product line includes branded gauze sponges and bandages, non-adherent impregnated dressings, retention devices, paste bandages and other compression devices for the medical markets.

Receive News & Ratings for Derma Sciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Derma Sciences Inc and related companies with MarketBeat.com's FREE daily email newsletter.